{"id":"https://openalex.org/W2603170664","doi":"https://doi.org/10.1507/endocrj.ej16-0552","title":"Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan","display_name":"Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan","publication_year":2017,"publication_date":"2017-01-01","ids":{"openalex":"https://openalex.org/W2603170664","doi":"https://doi.org/10.1507/endocrj.ej16-0552","mag":"2603170664","pmid":"https://pubmed.ncbi.nlm.nih.gov/28367916"},"language":"en","primary_location":{"id":"doi:10.1507/endocrj.ej16-0552","doi":"https://doi.org/10.1507/endocrj.ej16-0552","is_oa":true,"landing_page_url":"https://doi.org/10.1507/endocrj.ej16-0552","pdf_url":"https://www.jstage.jst.go.jp/article/endocrj/64/5/64_EJ16-0552/_pdf","source":{"id":"https://openalex.org/S191387813","display_name":"Endocrine Journal","issn_l":"0918-8959","issn":["0918-8959","1348-4540"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","medline","norway-1","oarl","poland-70","russia-white-list-3"],"host_organization":"https://openalex.org/P4310313267","host_organization_name":"Japan Endocrine Society","host_organization_lineage":["https://openalex.org/P4310313267"],"host_organization_lineage_names":["Japan Endocrine Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Endocrine Journal","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.jstage.jst.go.jp/article/endocrj/64/5/64_EJ16-0552/_pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087983151","display_name":"Yukiko Onishi","orcid":"https://orcid.org/0000-0003-1180-5982","observed_orcids":["https://orcid.org/0000-0003-1180-5982"]},"institutions":[{"id":"https://openalex.org/I4210087332","display_name":"The Institute of Medical Science, Asahi Life Foundation","ror":"https://ror.org/000hskt11","country_code":"JP","type":"other","lineage":["https://openalex.org/I4210087332"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yukiko Onishi","raw_affiliation_strings":["The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan","institution_ids":["https://openalex.org/I4210087332"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065510246","display_name":"Tomonori Oura","orcid":"https://orcid.org/0000-0003-0872-8576","observed_orcids":["https://orcid.org/0000-0003-0872-8576"]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomonori Oura","raw_affiliation_strings":["Eli Lilly Japan K.K., Kobe, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly Japan K.K., Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112480269","display_name":"Akiko Matsui","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akiko Matsui","raw_affiliation_strings":["Eli Lilly Japan K.K., Kobe, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly Japan K.K., Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jun Matsuura","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Jun Matsuura","raw_affiliation_strings":["Eli Lilly Japan K.K., Kobe, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly Japan K.K., Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"last","author":{"id":null,"display_name":"Noriyuki Iwamoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Noriyuki Iwamoto","raw_affiliation_strings":["Eli Lilly Japan K.K., Kobe, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly Japan K.K., Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.3601,"has_fulltext":true,"cited_by_count":49,"citation_normalized_percentile":{"value":0.79992965,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"64","issue":"5","first_page":"553","last_page":"560"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dulaglutide","display_name":"dulaglutide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9539999961853027},{"id":"https://openalex.org/keywords/sex-differences","display_name":"sex differences","score":0.9909999966621399},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.847000002861023},{"id":"https://openalex.org/keywords/hba1c-reduction","display_name":"HbA1c reduction","score":0.8119999766349792},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.8730000257492065},{"id":"https://openalex.org/keywords/nausea","display_name":"nausea","score":0.5870000123977661},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7289999723434448},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.8939999938011169},{"id":"https://openalex.org/keywords/insulin-glargine","display_name":"insulin glargine","score":0.9649999737739563},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.8690000176429749},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.43700000643730164},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.5490000247955322}],"concepts":[{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.9239262342453003},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8824458718299866},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.7003717422485352},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6496289968490601},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6379716396331787},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5810245275497437},{"id":"https://openalex.org/C2777538456","wikidata":"https://www.wikidata.org/wiki/Q311213","display_name":"Glycated hemoglobin","level":4,"score":0.5312872529029846},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.49470874667167664},{"id":"https://openalex.org/C2779920387","wikidata":"https://www.wikidata.org/wiki/Q417317","display_name":"Insulin glargine","level":4,"score":0.47955605387687683},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.45719659328460693},{"id":"https://openalex.org/C2780320433","wikidata":"https://www.wikidata.org/wiki/Q3403879","display_name":"Weight gain","level":3,"score":0.42657211422920227},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.4133349359035492},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.3984007239341736},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.24582543969154358},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.24337998032569885},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.24096521735191345},{"id":"https://openalex.org/C147583825","wikidata":"https://www.wikidata.org/wiki/Q620876","display_name":"Body weight","level":2,"score":0.12644904851913452}],"mesh":[{"descriptor_ui":"D000069036","descriptor_name":"Insulin Glargine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000069036","descriptor_name":"Insulin Glargine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012737","descriptor_name":"Sex Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1507/endocrj.ej16-0552","doi":"https://doi.org/10.1507/endocrj.ej16-0552","is_oa":true,"landing_page_url":"https://doi.org/10.1507/endocrj.ej16-0552","pdf_url":"https://www.jstage.jst.go.jp/article/endocrj/64/5/64_EJ16-0552/_pdf","source":{"id":"https://openalex.org/S191387813","display_name":"Endocrine Journal","issn_l":"0918-8959","issn":["0918-8959","1348-4540"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","medline","norway-1","oarl","poland-70","russia-white-list-3"],"host_organization":"https://openalex.org/P4310313267","host_organization_name":"Japan Endocrine Society","host_organization_lineage":["https://openalex.org/P4310313267"],"host_organization_lineage_names":["Japan Endocrine Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Endocrine Journal","raw_type":"journal-article"},{"id":"pmid:28367916","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28367916","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Endocrine journal","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":{"id":"doi:10.1507/endocrj.ej16-0552","doi":"https://doi.org/10.1507/endocrj.ej16-0552","is_oa":true,"landing_page_url":"https://doi.org/10.1507/endocrj.ej16-0552","pdf_url":"https://www.jstage.jst.go.jp/article/endocrj/64/5/64_EJ16-0552/_pdf","source":{"id":"https://openalex.org/S191387813","display_name":"Endocrine Journal","issn_l":"0918-8959","issn":["0918-8959","1348-4540"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","medline","norway-1","oarl","poland-70","russia-white-list-3"],"host_organization":"https://openalex.org/P4310313267","host_organization_name":"Japan Endocrine Society","host_organization_lineage":["https://openalex.org/P4310313267"],"host_organization_lineage_names":["Japan Endocrine Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Endocrine Journal","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2603170664.pdf","grobid_xml":"https://content.openalex.org/works/W2603170664.grobid-xml"},"referenced_works_count":16,"referenced_works":["https://openalex.org/W1883583237","https://openalex.org/W1887330886","https://openalex.org/W1906367066","https://openalex.org/W1951367122","https://openalex.org/W1980069619","https://openalex.org/W2004032034","https://openalex.org/W2018421152","https://openalex.org/W2040794084","https://openalex.org/W2126838326","https://openalex.org/W2174832318","https://openalex.org/W2182248589","https://openalex.org/W2210133271","https://openalex.org/W2219237166","https://openalex.org/W2262325221","https://openalex.org/W2336561662","https://openalex.org/W2515252105"],"related_works":["https://openalex.org/W2746628081","https://openalex.org/W2219237166","https://openalex.org/W4396742226","https://openalex.org/W4308771544","https://openalex.org/W4412548742","https://openalex.org/W4412917849","https://openalex.org/W2989874231","https://openalex.org/W2593929648","https://openalex.org/W2756342814","https://openalex.org/W2182248589"],"abstract_inverted_index":{"We":[0],"analyzed":[1],"the":[2,51,59,74,130,148,158,237],"efficacy":[3],"and":[4,36,54,78,110,195,223],"safety":[5,226],"of":[6,48,56,103,132,150,198,208],"once":[7],"weekly":[8],"dulaglutide":[9,211,230,241],"0.75":[10],"mg":[11],"by":[12,181],"sex":[13],"in":[14,21,50,58,67,107,122,147,160,165,168],"2":[15,26,166],"randomized,":[16],"controlled":[17],"phase":[18],"3":[19],"studies":[20,167],"Japanese":[22],"patients":[23,49,57,80,104,186,209],"with":[24,105],"type":[25],"diabetes":[27],"(a":[28],"52-week":[29],"monotherapy":[30,52],"study":[31,41,53],"[comparator":[32,42],"liraglutide":[33],"0.9":[34],"mg]":[35],"a":[37],"26-week":[38],"combination":[39,60],"therapy":[40,61],"insulin":[43],"glargine]).":[44],"Females":[45,85],"comprised":[46],"18%":[47],"29%":[55],"study.":[62],"Mean":[63],"reductions":[64,106],"from":[65,112],"baseline":[66,113],"glycated":[68],"hemoglobin":[69],"(HbA1c)":[70],"were":[71,114,155,217,231],"similar":[72],"between":[73,157],"sexes":[75,159],"for":[76,117,120,220,233,240,245],"dulaglutide-":[77],"liraglutide-treated":[79],"(range":[81],"-1.17%":[82],"to":[83,137,204,214,229],"-1.49%).":[84],"had":[86,187],"numerically":[87],"greater":[88,116,139,188,196],"weight":[89,93,111,189,193],"loss":[90,190],"or":[91,152,191],"less":[92,192],"gain":[94,194],"than":[95,119,142],"males":[96,121],"across":[97,170],"all":[98,123,127,171],"treatment":[99,124,128,162,172],"groups.":[100,125],"The":[101],"percentages":[102],"both":[108,221,246],"HbA1c":[109,177],"also":[115],"females":[118,141],"In":[126],"groups,":[129],"incidences":[131,149],"treatment-emergent":[133],"adverse":[134,199,215],"events":[135],"tended":[136],"be":[138],"among":[140,143],"males.":[144],"No":[145],"differences":[146],"total":[151],"nocturnal":[153],"hypoglycemia":[154],"observed":[156],"any":[161],"group.":[163],"Overall,":[164],"Japan,":[169],"groups":[173],"it":[174],"appeared":[175],"that":[176],"lowering":[178],"was":[179],"unaffected":[180],"patient":[182],"sex,":[183],"while":[184],"female":[185],"incidence":[197],"events,":[200],"including":[201],"nausea,":[202],"compared":[203],"male":[205],"patients.":[206],"Incidences":[207],"discontinuing":[210],"early":[212],"due":[213],"event":[216],"low":[218],"(<10%)":[219],"sexes,":[222],"no":[224],"new":[225],"concerns":[227],"related":[228],"identified":[232],"either":[234],"sex.":[235],"Therefore,":[236],"benefit/risk":[238],"ratio":[239],"remains":[242],"unchanged,":[243],"positive":[244],"sexes.":[247]},"counts_by_year":[{"year":2026,"cited_by_count":9},{"year":2025,"cited_by_count":13},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2017-04-07T00:00:00"}